FAM184A

Across TCGA pan-cancer cohorts, FAM184A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM184A data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FAM184A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM184A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and SARC are the cancer types where FAM184A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.140	0.740	<.001	19	view →
UCEC	DFS	Median	II,III,IV	0.928	0.436	.021	14	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.698	0.850	.009	5	view →
COAD	OS	Median	III,IV	0.183	0.696	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM184A–LUSC (OS)

Open the LUSC breakdown →